%0 Journal Article %A Mukta G. Palshikar %A Rohith Palli %A Alicia Tyrell %A Sanjay Maggirwar %A Giovanni Schifitto %A Meera V. Singh %A Juilee Thakar %T Executable models of immune signaling pathways in HIV-associated atherosclerosis %D 2022 %R 10.1101/2022.03.07.22271522 %J medRxiv %P 2022.03.07.22271522 %X Atherosclerosis (AS)-associated cardiovascular disease is an important cause of mortality in an aging population of people living with HIV (PLWH). This elevated risk has been attributed to viral infection, anti-retroviral therapy, chronic inflammation, and lifestyle factors. However, rates at which PLWH develop AS vary even after controlling for length of infection, treatment duration, and for lifestyle factors. To investigate the molecular signaling underlying this variation, we sequenced 9368 peripheral blood mononuclear cells (PBMCs) from eight PLWH, four of whom have atherosclerosis (AS+). Additionally, a publicly available dataset of PBMCs from persons before and after HIV infection was used to investigate the effect of acute HIV infection. To characterize dysregulation of pathways rather than just measuring enrichment, we developed the single-cell Boolean Omics Network Invariant Time Analysis (scBONITA) algorithm. scBONITA infers executable dynamic pathway models and performs perturbation analysis to identify high impact genes. These dynamic models are used for pathway analysis and to map sequenced cells to characteristic signaling states (attractor analysis). scBONITA revealed that lipid signaling regulates cell migration into the vascular endothelium in AS+ PLWH. Pathways implicated included AGE-RAGE and PI3K-AKT signaling in CD8+ T cells, and glucagon and cAMP signaling pathways in monocytes. Attractor analysis with scBONITA facilitated pathway-based characterization of cellular states in CD8+ T cells and monocytes. In this manner, we identify critical cell-type specific molecular mechanisms underlying HIV-associated atherosclerosis using a novel computational method.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by U.S. National Institutes of Health. MGP is supported by R01 AI134058. RP is supported by T32 GM07356. JT was supported by UM1 AI069511, P30 AI078498, R01 AI134058 and R21 AI136668. SBM, GS and AT were supported by R01 HL123346, SBM and MVS are supported by R01 HL128155, R01 NS066801. The University of Rochester Center for AIDS Research (UR-CFAR; P30 AI078498) provided support and core facilities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All methods were carried out in accordance with University of Rochester guidelines and regulations, and all experimental and study protocols were approved by the University of Rochester Institutional Review Board (#RSRB00063845). The project does not qualify as human subjects research (45 CFR 46.102) in that the activities do not involve human subjects as defined in the federal regulations because this project utilizes anonymous information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe HIV/AS scRNA-seq dataset presented in this manuscript has been deposited in NCBI's Gene Expression Omnibus and will be made accessible through GEO Series accession number GSE198339 on publication of the manuscript. Due to the sensitive nature of HIV data, we have not made the raw data public. All results presented in this manuscript may be recapitulated from the raw count data, processed data, and metadata in GEO. We also analyzed a previously published dataset that is freely accessible at https://singlecell.broadinstitute.org/single_cell/study/SCP256. All source code, tutorials, and documentation for the scBONITA Python package are available at https://github.com/Thakar-Lab/scBONITA. %U https://www.medrxiv.org/content/medrxiv/early/2022/07/05/2022.03.07.22271522.full.pdf